Sandoz, a prominent producer of generic and biosimilar medicines, has announced that the biosimilar drug, Tyruko (natalizumab), will be released in Germany from February 1st.
Developed by Polpharma Biologics, Tyruko is the first and only biosimilar designed to treat adults suffering from highly active relapsing remitting multiple sclerosis, or RRMS. Sandoz and Polpharma Biologics entered into an agreement to globally commercialize Tyruko, a biosimilar natalizumab, in 2019.
Tyruko is prescribed as a standalone disease-modifying therapy (DMT) for adults with highly active RRMS, which aligns with the indication approved by the European Commission for the reference medicine, Tysabri.
Rebecca Guntern, President of Sandoz Europe, emphasizes the pivotal role of timely treatment with disease-modifying therapies on the overall well-being and future disabilities of individuals with multiple sclerosis. As the only biosimilar in this realm, the introduction of Tyruko presents a significant benchmark in broadening the accessibility of effective and safe interventions for the European population in vital need of these treatments.
According to the aforementioned global commercialization agreement, the development, manufacturing, and supply of the medicine remains under the responsibility of Polpharma Biologics, while Sandoz is granted exclusive global licensure rights to commercialize and distribute Tyruko across all markets.
For more news on health, please visit rttnews.com.
